Recursion Pharmaceuticals Drops 11.8% Monthly; Q1 EPS Seen Improving 46%
Shares of Recursion Pharmaceuticals slipped 1.99% in the latest session, underperforming major indexes and falling 11.8% over the past month versus a 1.9% sector decline. Analysts forecast Q1 EPS of −$0.27 (up 46% year-over-year) on $20.7 million revenue (up 40.7%).
1. Market Performance
Shares fell 1.99% in the latest session, underperforming the S&P 500's 0.21% loss, the Dow's 0.07% drop and the Nasdaq's 0.01% gain.
2. Monthly Trend vs Sector
Over the past month, shares declined 11.81%, trailing the Medical sector's 1.9% drop and the S&P 500's 2.26% decrease.
3. Quarterly and Full-Year Forecasts
Analysts forecast Q1 EPS of −$0.27, a 46% year-over-year improvement, on revenue of $20.7 million, up 40.7%. Full-year estimates call for EPS of −$0.93 (up 35.4%) and revenue of $90.5 million (up 21.2%).
4. Analyst Revisions and Industry Standing
Consensus EPS projections rose 9.98% in the past 30 days, reinforcing a Hold rating. The Medical – Biomedical and Genetics industry ranks in the top 36% of over 250 industries based on average analyst ratings.